Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

827.09 -17.32 (-2.05%)
Streaming Delayed Price Updated: 3:52 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

News headline image
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Analyst Ratings for argenx ↗
 
Via Benzinga
Expert Ratings for argenx ↗
 
Via Benzinga
News headline image
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position ↗
 
Via Benzinga
News headline image
argenx Enters Into Agreement To Acquire Priority Review Voucher
From argenx SE
Via GlobeNewswire
News headline image
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review ↗
 
Via Benzinga
News headline image
7 Analysts Have This to Say About argenx ↗
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Argenx's Drug Scores European Approval For Muscular Fatigue Disorder ↗
 
Via Benzinga
News headline image
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
News headline image
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday ↗
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at... 
Via Benzinga
News headline image
Recap: argenx Q3 Earnings ↗
argenx (NASDAQ:ARGX) reported its Q3 earnings results on Thursday, October 27, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx missed estimated earnings by... 
Via Benzinga
News headline image
argenx: Q2 Earnings Insights ↗
  argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap: argenx Q2 Earnings ↗
  argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About argenx ↗
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter: 
Via Benzinga
News headline image
SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space ↗
 
Via Benzinga
News headline image
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
From argenx SE
Via GlobeNewswire
News headline image
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say ↗
 
Via Benzinga
News headline image
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection ↗
 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate ↗
The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022 ↗
  
Via Benzinga
News headline image
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know ↗
Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.